The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options for adults with moderate to severe active Crohn disease.

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...

Tildrakizumab showed early and sustained effectiveness and quality of life (QOL) improvements in patients with moderate to ...

Janssen’s Tremfya (guselkumab) psoriasis drug has been launched in the UK, where it hopes to steal sales from a crowd of well-established drugs such as Novartis’ Cosentyx. The launch in ...